Complexities of androgen receptor signalling in breast cancer

Endocrine-Related Cancer

Volumn 21, Issue 4, 2014, Pages

  McNamara, Keely M ^a   Moore, Nicole L ^b   Hickey, Theresa E ^b   Sasano, Hironobu ^a   Tilley, Wayne D ^b  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b University of Adelaide   (Australia)

Author keywords

Androgen; Androgen regulated pathways; Breast cancer; Intracrinology; Outcome; Risk

Indexed keywords

3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; 3ALPHA HYDROXYSTEROID DEHYDROGENASE; ANDROGEN; ANDROGEN RECEPTOR; AROMATASE; BICALUTAMIDE; DACTOLISIB; ENZALUTAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GLUCURONOSYLTRANSFERASE; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; STEROID 5ALPHA REDUCTASE; STERYL SULFATASE; TESTOSTERONE; TESTOSTERONE 17BETA DEHYDROGENASE; AR PROTEIN, HUMAN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN;

ANDROGEN METABOLISM; APOCRINE BREAST CANCER; APOCRINE GLAND; BASAL BREAST CANCER; BREAST CANCER; CANCER PROGNOSIS; CANCER RISK; CELL CYCLE; EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; ESTROGEN RECEPTOR NEGATIVE BREAST CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HUMAN; META ANALYSIS (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; PREMENOPAUSE; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TESTOSTERONE BLOOD LEVEL; TRIPLE NEGATIVE BREAST CANCER; ANIMAL; BREAST NEOPLASMS; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHYSIOLOGY; PROGNOSIS;

ANDROGENS; ANIMALS; BREAST NEOPLASMS; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROGNOSIS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84905996424     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-14-0243     Document Type: Review

References (198)

1. Adly L, Hill D, Sherman ME, Sturgeon SR, Fears T, Mies C, Ziegler RG, Hoover RN & Schairer C 2006 Serum concentrations of estrogens, sex hormone-binding globulin, and androgens and risk of breast cancer in postmenopausal women. International Journal of Cancer 119 2402-2407. (doi:10.1002/ijc.22203)
2. Agoff SN, Swanson PE, Linden H, Hawes SE & Lawton TJ 2003 Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. American Journal of Clinical Pathology 120 725-731. (doi:10.1309/42F00D0DJD0J5EDT)
3. Agrawal AK, Jelen M, Grzebieniak Z, Zukrowski P, Rudnicki J & Nienartowicz E 2008 Androgen receptors as a prognostic and predictive factor in breast cancer. Folia Histochemica et Cytobiologica 46 269-276. (doi:10.2478/v10042-008-0039-y)
4. Allegra JC, Lippman ME, Simon R, Thompson EB, Barlock A, Green L, Huff KK, Do HM, Aitken SC & Warren R 1979 Association between steroid hormone receptor status and disease-free interval in breast cancer. Cancer Treatment Reports 63 1271-1277. (Pubitemid 10187969)
5. Ando S, De Amicis F, Rago V, Carpino A, Maggiolini M, Panno ML & Lanzino M 2002 Breast cancer: from estrogen to androgen receptor. Molecular and Cellular Endocrinology 193 121-128. (doi:10.1016/S0303-7207(02)00105-3)
6. Asscheman H, Giltay EJ, Megens JA, de Ronde WP, van Trotsenburg MA & Gooren LJ 2011 A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. European Journal of Endocrinology 164 635-642. (doi:10.1530/EJE-10-1038)
7. Augello MA, Hickey TE & Knudsen KE 2011 FOXA1: master of steroid receptor function in cancer. EMBO Journal 30 3885-3894. (doi:10.1038/emboj.2011. 340)
8. Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR et al. 2011 Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Modern Pathology 24 157-167. (doi:10.1038/ modpathol.2010.200)
9. Baglietto L, Severi G, English DR, Krishnan K, Hopper JL, McLean C, Morris HA, Tilley WD & Giles GG 2010 Circulating steroid hormone levels and risk of breast cancer for postmenopausal women. Cancer Epidemiology, Biomarkers & Prevention 19 492-502. (doi:10.1158/1055-9965.EPI-09-0532)
10. Barcellos-Hoff MH 2013 Doesmicroenvironment contribute to the etiology of estrogen receptor-negative breast cancer? Clinical Cancer Research 19 541-548. (doi:10.1158/1078-0432.CCR-12-2241)
11. Bentz EK, Pils D, Bilban M, Kaufmann U, Hefler LA, Reinthaller A, Singer CF, Huber JC, Horvat R & Tempfer CB 2010 Gene expression signatures of breast tissue before and after cross-sex hormone therapy in female-to-male transsexuals. Fertility and Sterility 94 2688-2696. (doi:10.1016/j.fertnstert. 2010.04.024)
12. Berns EM, Dirkzwager-Kiel MJ, Kuenen-Boumeester V, Timmermans M, Verhoog LC, van den Ouweland AM, Meijer-Heijboer H, Klijn JG & van der Kwast TH 2003 Androgen pathway dysregulation in BRCA1-mutated breast tumors. Breast Cancer Research and Treatment 79 121-127. (doi:10.1023/A:1023347409599)
13. Berrino F, Pasanisi P, Bellati C, Venturelli E, Krogh V, Mastroianni A, Berselli E, Muti P & Secreto G 2005 Serum testosterone levels and breast cancer recurrence. International Journal of Cancer 113 499-502. (doi:10.1002/ijc.20582)
14. Bharaj B, Scorilas A, Giai M & Diamandis EP 2000 TA repeat polymorphism of the 5α-reductase gene and breast cancer. Cancer Epidemiology, Biomarkers & Prevention 9 387-393. (Pubitemid 30265782)
15. Bieche I, Parfait B, Tozlu S, Lidereau R & Vidaud M 2001 Quantitation of androgen receptor gene expression in sporadic breast tumors by real-time RT-PCR: evidence that MYC is an AR-regulated gene. Carcinogenesis 22 1521-1526. (doi:10.1093/carcin/22.9.1521)
16. Birrell SN, Bentel JM, Hickey TE, Ricciardelli C, Weger MA, Horsfall DJ & Tilley WD 1995 Androgens induce divergent proliferative responses in human breast cancer cell lines. Journal of Steroid Biochemistry and Molecular Biology 52 459-467. (doi:10.1016/0960-0760(95)00005-K)
17. Braunstein GD 2007 Safety of testosterone treatment in postmenopausal women. Fertility and Sterility 88 1-17. (doi:10.1016/j.fertnstert.2007.01.118)
18. Braunstein GD, Reitz RE, Buch A, Schnell D & Caulfield MP 2011 Testosterone reference ranges in normally cycling healthy premenopausal women. Journal of Sexual Medicine 8 2924-2934. (doi:10.1111/j.1743-6109.2011.02380.x)
19. Bryan RM, Mercer RJ, Bennett RC, Rennie GC, Lie TH & Morgan FJ 1984 Androgen receptors in breast cancer. Cancer 54 2436-2440. (doi:10.1002/1097- 0142(19841201)54:11〈2436::AID-CNCR2820541121〉3.0.CO;2-H)
20. Bui HN, Sluss PM, Blincko S, Knol DL, Blankenstein MA & Heijboer AC 2013 Dynamics of serum testosterone during the menstrual cycle evaluated by daily measurements with an ID-LC-MS/MS method and a 2nd generation automated immunoassay. Steroids 78 96-101. (doi:10.1016/j.steroids.2012.10.010)
21. Burger HG 2002 Androgen production in women. Fertility and Sterility 77 (Suppl 4) S3-S5. (doi:10.1016/S0015-0282(02)02985-0)
22. Burgess HE & Shousha S 1993 An immunohistochemical study of the long-term effects of androgen administration on female-to-male transsexual breast: a comparison with normal female breast and male breast showing gynaecomastia. Journal of Pathology 170 37-43. (doi:10.1002/path.1711700107)
23. Byrns MC & Penning TM 2009 Type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs. Chemico-Biological Interactions 178 221-227. (doi:10.1016/j.cbi.2008.10.024)
24. Byrns MC, Duan L, Lee SH, Blair IA & Penning TM 2010 Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer. Journal of Steroid Biochemistry and Molecular Biology 118 177-187. (doi:10.1016/j.jsbmb.2009.12.009)
25. Cancer Genome Atlas N 2012 Comprehensive molecular portraits of human breast tumours. Nature 490 61-70. (doi:10.1038/nature11412)
26. Carreno G, Del Casar JM, Corte MD, Gonzalez LO, Bongera M, Merino AM, Juan G, Obregon R, Martinez E & Vizoso FJ 2007 Local recurrence after mastectomy for breast cancer: analysis of clinicopathological, biological and prognostic characteristics. Breast Cancer Research and Treatment 102 61-73. (doi:10.1007/s10549-006-9310-0)
27. Castellano I, Allia E, Accortanzo V, Vandone AM, Chiusa L, Arisio R, Durando A, Donadio M, Bussolati G, Coates AS et al. 2010 Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Research and Treatment 124 607-617. (doi:10.1007/s10549-010-0761-y)
28. Castellano I, Chiusa L, Vandone AM, Beatrice S, Goia M, Donadio M, Arisio R, Muscara F, Durando A, Viale G et al. 2013 A simple and reproducible prognostic index in luminal ER-positive breast cancers. Annals of Oncology 24 2292-2297. (doi:10.1093/annonc/mdt183)
29. Chang C, Lee SO, Wang RS, Yeh S & Chang TM 2013 Androgen receptor (AR) physiological roles in male and female reproductive systems: lessons learned from AR-knockout mice lacking AR in selective cells. Biology of Reproduction 89 21. (doi:10.1095/biolreprod.113.109132)
30. Chanplakorn N, Chanplakorn P, Suzuki T, Ono K, Chan MS, Miki Y, Saji S, Ueno T, Toi M & Sasano H 2010 Increased estrogen sulfatase (STS) and 17β-hydroxysteroid dehydrogenase type 1(17β-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients. Breast Cancer Research and Treatment 120 639-648. (doi:10.1007/s10549-010-0785-3)
31. Chanplakorn N, Chanplakorn P, Suzuki T, Ono K, Wang L, Chan MS, Wing L, Yiu CC, Chow LW & Sasano H 2011 Increased 5α-reductase type 2 expression in human breast carcinoma following aromatase inhibitor therapy: the correlation with decreased tumor cell proliferation. Hormones & Cancer 2 73-81. (doi:10.1007/s12672-010-0062-2)
32. Chen J, Wang WQ & Lin SX 2013 Interaction of androst-5-ene-3β, 17β-diol and 5α-androstane-3β,17β-diol with estrogen and androgen receptors: a combined binding and cell study. Journal of Steroid Biochemistry and Molecular Biology 137 316-321. (doi:10.1016/j.jsbmb.2013.01. 012)
33. Cheng G, Li Y, Omoto Y, Wang Y, Berg T, Nord M, Vihko P, Warner M, \kern-2ptPiao YS & Gustafsson JA 2005 Differential regulation of estrogen receptor (ER)α and ERβ in primate mammary gland. Journal of Clinical Endocrinology and Metabolism 90 435-444. (doi:10.1210/jc.2004-0861)
34. Chia KM, Liu J, Francis GD & Naderi A 2011 A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer. Neoplasia 13 154-166.
35. Chintamani, Kulshreshtha P, Chakraborty A, Singh L, Mishra AK, Bhatnagar D & Saxena S 2010 Androgen receptor status predicts response to chemotherapy, not risk of breast cancer in Indian women. World Journal of Surgical Oncology 8 64. (doi:10.1186/1477-7819-8-64)
36. Cleator S, Heller W & Coombes RC 2007 Triple-negative breast cancer: therapeutic options. Lancet Oncology 8 235-244. (doi:10.1016/S1470-2045(07) 70074-8)
37. Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D Amato NC, Spoelstra NS, Edgerton SM, Jean A, Guerrero J et al. 2014 Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Research 16 R7. (doi:10.1186/bcr3599)
38. Collins LC, Cole KS, Marotti JD, Hu R, Schnitt SJ & Tamimi RM 2011 Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. Modern Pathology 24 924-931. (doi:10.1038/modpathol.2011.54)
39. Cops EJ, Bianco-Miotto T, Moore NL, Clarke CL, Birrell SN, Butler LM & Tilley WD 2008 Antiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells are mediated by both androgen and progesterone receptors. Journal of Steroid Biochemistry and Molecular Biology 110 236-243. (doi:10.1016/j.jsbmb.2007.10.014)
40. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y et al. 2012 The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486 346-352. (doi:10.1038/nature10983)
41. Davis SR 2010 Should women receive androgen replacement therapy, and if so, how? Clinical Endocrinology 72 149-154. (doi:10.1111/j.1365-2265.2009.03670. x)
42. De Amicis F, Thirugnansampanthan J, Cui Y, Selever J, Beyer A, Parra I, Weigel NL, Herynk MH, Tsimelzon A, Lewis MT et al. 2010 Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Research and Treatment 121 1-11. (doi:10.1007/s10549-009-0436-8)
43. Dimitrakakis C, Zhou J, Wang J, Belanger A, LaBrie F, Cheng C, Powell D & Bondy C 2003 A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause 10 292-298. (doi:10.1097/01.GME.0000055522. 67459.89)
44. Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C & Gerald WL 2006 An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25 3994-4008. (doi:10.1038/sj.onc.1209415)
45. Dorgan JF, Stanczyk FZ, Kahle LL & Brinton LA 2010 Prospective case-control study of premenopausal serum estradiol and testosterone levels and breast cancer risk. Breast Cancer Research 12 R98. (doi:10.1186/bcr2779)
46. Dufort I, Rheault P, Huang XF, Soucy P & Luu-The V 1999 Characteristics of a highly labile human type 5 17β-hydroxysteroid dehydrogenase. Endocrinology 140 568-574. (Pubitemid 29058186)
47. Eigeliene N, Elo T, Linhala M, Hurme S, Erkkola R & Härkönen P 2012 Androgens inhibit the stimulatory action of 17β-estradiol on normal human breast tissue in explant cultures. Journal of Clinical Endocrinology and Metabolism 97 E1116-E1127. (doi:10.1210/jc.2011- 3228)
48. Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M & Hankinson SE 2006 Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. Journal of the National Cancer Institute 98 1406-1415. (doi:10.1093/jnci/djj376)
49. Farhat GN, Cummings SR, Chlebowski RT, Parimi N, Cauley JA, Rohan TE, Huang AJ, Vitolins M, Hubbell FA, Manson JE et al. 2011 Sex hormone levels and risks of estrogen receptor-negative and estrogen receptor-positive breast cancers. Journal of the National Cancer Institute 103 562-570. (doi:10.1093/jnci/djr031)
50. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, Macgrogan G, Bergh J, Cameron D, Goldstein D et al. 2005 Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 24 4660-4671. (doi:10.1038/sj.onc.1208561)
51. Fourkala EO, Zaikin A, Burnell M, Gentry-Maharaj A, Ford J, Gunu R, Soromani C, Hasenbrink G, Jacobs I, Dawnay A et al. 2012 Association of serum sex steroid receptor bioactivity and sex steroid hormones with breast cancer risk in postmenopausal women. Endocrine-Related Cancer 19 137-147. (doi:10.1530/ERC-11-0310)
52. Francis A, Sarkar S, Pooja S, Surekha D, Rao DR, Rao L, Ramachandra L, Vishnupriya S, Satyamoorthy K, Thangaraj K et al. 2014 SRD5A2 gene polymorphisms affect the risk of breast cancer. Breast 2 137-141. (doi:10.1016/j.breast.2013. 11.010)
53. Garay JP, Karakas B, Abukhdeir AM, Cosgrove DP, Gustin JP, Higgins MJ, Konishi H, Konishi Y, Lauring J, Mohseni M et al. 2012 The growth response to androgen receptor signaling in ERα-negative human breast cells is dependent on p21 and mediated by MAPK activation. Breast Cancer Research 14 R27. (doi:10.1186/bcr3112)
54. Geisler J, Sasano H, Chen S & Purohit A 2011 Steroid sulfatase inhibitors: promising new tools for breast cancer therapy? Journal of Steroid Biochemistry and Molecular Biology 125 39-45. (doi:10.1016/j.jsbmb.2011.02.002)
55. van Gils CH, Onland-Moret NC, Roest M, van Noord PA & Peeters PH 2003 The V89L polymorphism in the 5-α-reductase type 2 gene and risk of breast cancer. Cancer Epidemiology, Biomarkers & Prevention 12 1194-1199. (Pubitemid 37499443)
56. Gonzalez LO, Corte MD, Vazquez J, Junquera S, Sanchez R, Alvarez AC, Rodriguez JC, Lamelas ML & Vizoso FJ 2008 Androgen receptor expression in breast cancer: relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors. BMC Cancer 8 149. (doi:10.1186/1471-2407-8-149)
57. Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, Carey M, Agarwal R, Meric-Berstam F, Traina TA, Hudis C, Hortobagyi GN, Gerald WL et al. 2009 Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clinical Cancer Research 15 2472-2478. (doi:10.1158/1078-0432. CCR-08-1763)
58. Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell K, Rugo H, Nabell L, Forero A et al. 2013 Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clinical Cancer Research 19 5505-5512. (doi:10.1158/1078-0432. CCR-12-3327)
59. Haakensen VD, Biong M, Lingjærde OC, Holmen MM, Frantzen JO, Chen Y, Navjord D, Romundstad L, Lüders T, Bukholm IK et al. 2010 Expression levels of uridine 5′-diphospho-glucuronosyltransferase genes in breast tissue from healthy women are associated with mammographic density. Breast Cancer Research 12 R65. (doi:10.1186/bcr2632)
60. Hackenberg R, Hofmann J, Holzel F & Schulz KD 1988 Stimulatory effects of androgen and antiandrogen on the in vitro proliferation of human mammary carcinoma cells. Journal of Cancer Research and Clinical Oncology 114 593-601. (doi:10.1007/BF00398183)
61. Hackenberg R, Luttchens S, Hofmann J, Kunzmann R, Holzel F & Schulz KD 1991 Androgen sensitivity of the new human breast cancer cell line MFM-223. Cancer Research 51 5722-5727.
62. Hackenberg R, Hawighorst T, Filmer A, Nia AH & Schulz KD 1993 Medroxyprogesterone acetate inhibits the proliferation of estrogen- and progesterone-receptor negative MFM-223 human mammary cancer cells via the androgen receptor. Breast Cancer Research and Treatment 25 217-224. (doi:10.1007/BF00689836)
63. Hall RE, Birrell SN, Tilley WD & Sutherland RL 1994 MDA-MB-453, an androgen-responsive human breast carcinoma cell line with high level androgen receptor expression. European Journal of Cancer 30A 484-490. (doi:10.1016/0959-8049(94)90424-3)
64. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M et al. 2010 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Archives of Pathology & Laboratory Medicine 134 e48-e72. (doi:10.1043/1543-2165-134.6.907)
65. Han B, Li S, Song D, Poisson-Pare D, Liu G, Luu-The V, Ouellet J, Labrie F & Pelletier G 2008 Expression of 17β-hydroxysteroid dehydrogenase type 2 and type 5 in breast cancer and adjacent non-malignant tissue: a correlation to clinicopathological parameters. Journal of Steroid Biochemistry and Molecular Biology 112 194-200. (doi:10.1016/j.jsbmb.2008.10.004)
66. Hankinson SE, Willett WC, Manson JE, Colditz GA, Hunter DJ, Spiegelman D, Barbieri RL & Speizer FE 1998 Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. Journal of the National Cancer Institute 90 1292-1299. (doi:10.1093/jnci/90.17.1292)
67. Hanley K, Wang J, Bourne P, Yang Q, Gao AC, Lyman G & Tang P 2008 Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast. Human Pathology 39 386-392. (doi:10.1016/j.humpath. 2007.07.007)
68. Harrington WR, Sengupta S & Katzenellenbogen BS 2006 Estrogen regulation of the glucuronidation enzyme UGT2B15 in estrogen receptor-positive breast cancer cells. Endocrinology 147 3843-3850. (doi:10.1210/en.2006-0358)
69. Harwood DT & Handelsman DJ 2009 Development and validation of a sensitive liquid chromatography-tandem mass spectrometry assay to simultaneously measure androgens and estrogens in serum without derivatization. Clinica Chimica Acta 409 78-84. (doi:10.1016/j.cca.2009.09.003)
70. He J, Peng R, Yuan Z, Wang S, Peng J, Lin G, Jiang X & Qin T 2012 Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Medical Oncology 29 406-410. (doi:10.1007/s12032-011-9832-0)
71. Hickey TE, Robinson JL, Carroll JS & Tilley WD 2012 Minireview: the androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene? Molecular Endocrinology 26 1252-1267. (doi:10.1210/me.2012-1107)
72. Hofling M, Hirschberg AL, Skoog L, Tani E, Hagerstrom T & von Schoultz B 2007 Testosterone inhibits estrogen/progestogen-induced breast cell proliferation in postmenopausal women. Menopause 14 183-190. (doi:10.1097/01.gme.0000232033.92411.51)
73. Honma N, Saji S, Hirose M, Horiguchi SI, Kuroi K, Hayashi SI, Utsumi T & Harada N 2011 Sex steroid hormones in pairs of tumor and serum from breast cancerpatients andpathobiological roleofandrostene-3β, 17β-diol. Cancer Science 102 1848-1854. (doi:10.1111/j.1349-7006.2011.02018.x)
74. Honma N, Horii R, Iwase T, Saji S, Younes M, Ito Y & Akiyama F 2013 Clinical importance of androgen receptor in breast cancer patients treated with adjuvant tamoxifen monotherapy. Breast Cancer 20 323-330. (doi:10.1007/s12282- 012-0337-2)
75. Horwitz KB, Zava DT, Thilagar AK, Jensen EM & McGuire WL 1978 Steroid receptor analyses of nine human breast cancer cell lines. Cancer Research 38 2434-2437. (Pubitemid 8390817)
76. Hu R, Dawood S, Holmes MD, Collins LC, Schnitt SJ, Cole K, Marotti JD, Hankinson SE, Colditz GA & Tamimi RM 2011 Androgen receptor expression and breast cancer survival in postmenopausal women. Clinical Cancer Research 17 1867-1874. (doi:10.1158/1078-0432.CCR-10-2021)
77. Iggo RD 2011 New insights into the role of androgen and oestrogen receptors in molecular apocrine breast tumours. Breast Cancer Research 13 318. (doi:10.1186/bcr3036)
78. Ingle JN, Twito DI, Schaid DJ, Cullinan SA, Krook JE, Mailliard JA, Tschetter LK, Long HJ, Gerstner JG, Windschitl HE et al. 1991 Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis. Cancer 67 886-891. (doi:10.1002/1097-0142(19910215)67:4〈886::AID- CNCR2820670405〉3.0.CO;2-O)
79. Jin Y & Penning TM 2006 Multiple steps determine the overall rate of the reduction of 5α-dihydrotestosterone catalyzed by human type 3 3α-hydroxysteroid dehydrogenase: implications for the elimination of androgens. Biochemistry 45 13054-13063. (doi:10.1021/bi060591r)
80. Kaaks R, Berrino F, Key T, Rinaldi S, Dossus L, Biessy C, Secreto G, Amiano P, Bingham S, Boeing H et al. 2005a Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). Journal of the National Cancer Institute 97 755-765. (doi:10.1093/jnci/dji132)
81. Kaaks R, Rinaldi S, Key TJ, Berrino F, Peeters PH, Biessy C, Dossus L, Lukanova A, Bingham S, Khaw KT et al. 2005b Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocrine-Related Cancer 12 1071-1082. (doi:10.1677/erc.1.01038)
82. Kao KJ, Chang KM, Hsu HC & Huang AT 2011 Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization. BMC Cancer 11 143. (doi:10.1186/1471- 2407-11-143)
83. Key T, Appleby P, Barnes I & Reeves G 2002 Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. Journal of the National Cancer Institute 94 606-616. (doi:10.1093/jnci/94.8.606)
84. Kollara A, Kahn HJ, Marks A & Brown TJ 2001 Loss of androgen receptor associated protein 70 (ARA70) expression in a subset of HER2-positive breast cancers. Breast Cancer Research and Treatment 67 245-253. (doi:10.1023/A: 1017938608460)
85. Koo JS, Jung W & Jeong J 2009 The predictive role of E-cadherin and androgen receptor on in vitro chemosensitivity in triple-negative breast cancer. Japanese Journal of Clinical Oncology 39 560-568. (doi:10.1093/jjco/hyp065)
86. Krapf JM & Simon JA 2009 The role of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women. Maturitas 63 213-219. (doi:10.1016/j.maturitas.2009.04.008)
87. Kuenen-Boumeester V, Van der Kwast TH, van Putten WL, Claassen C, van Ooijen B & Henzen-Logmans SC 1992 Immunohistochemical determination of androgen receptors in relation to oestrogen and progesterone receptors in female breast cancer. International Journal of Cancer 52 581-584. (doi:10.1002/ijc. 2910520415)
88. Labrie F 1991 Intracrinology. Molecular and Cellular Endocrinology 78 C113-C118. (doi:10.1016/0303-7207(91)90116-A)
89. Labrie F & Labrie C 2012 DHEA and intracrinology at menopause, a positive choice for evolution of the human species. Climacteric 16 205-213. (doi:10.3109/13697137.2012.733983)
90. Labrie F, Luu-The V, Labrie C, Belanger A, Simard J, Lin SX & Pelletier G 2003 Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocrine Reviews 24 152-182. (doi:10.1210/er.2001-0031)
91. Langer M, Kubista E, Schemper M & Spona J 1990 Androgen receptors, serum androgen levels and survival of breast cancer patients. Archives of Gynecology and Obstetrics 247 203-209. (doi:10.1007/BF02389545)
92. Lanzino M, De Amicis F, McPhaul MJ, Marsico S, Panno ML & Ando S 2005 Endogenous coactivator ARA70 interacts with estrogen receptor α (ERα) and modulates the functional ERα/androgen receptor interplay in MCF-7 cells. Journal of Biological Chemistry 280 20421-20430. (doi:10.1074/jbc.M413576200)
93. Lanzino M, Sisci D, Morelli C, Garofalo C, Catalano S, Casaburi I, Capparelli C, Giordano C, Giordano F, Maggiolini M et al. 2010 Inhibition of cyclin D1 expression by androgen receptor in breast cancer cells - identification of a novel androgen response element. Nucleic Acids Research 38 5351-5365. (doi:10.1093/nar/gkq278)
94. Lanzino M, Maris P, Sirianni R, Barone I, Casaburi I, Chimento A, Giordano C, Morelli C, Sisci D, Rizza P et al. 2013 DAX-1, as an androgen-target gene, inhibits aromatase expression: a novel mechanism blocking estrogen-dependent breast cancer cell proliferation. Cell Death & Disease 4 e724. (doi:10.1038/cddis.2013.235)
95. Lapointe J, Fournier A, Richard V & Labrie C 1999 Androgens down-regulate bcl-2 protooncogene expression in ZR-75-1 human breast cancer cells. Endocrinology 140 416-421. (doi:10.1210/endo.140.1.6410)
96. Lea OA, Kvinnsland S &Thorsen T 1989 Improved measurement of androgen receptors in human breast cancer. Cancer Research 49 7162-7167. (Pubitemid 20016610)
97. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y & Pietenpol JA 2011 Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. Journal of Clinical Investigation 121 2750-2767. (doi:10.1172/JCI45014)
98. Lehmann-Che J, Hamy AS, Porcher R, Barritault M, Bouhidel F, Habuellelah H, Leman-Detours S, de Roquancourt A, Cahen-Doidy L, Bourstyn E et al. 2013 Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15. Breast Cancer Research 15 R37. (doi:10.1186/bcr3421)
99. Lewis MJ, Wiebe JP & Heathcote JG 2004 Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma. BMC Cancer 4 27. (doi:10.1186/1471-2407-4-27)
100. Loibl S, Muller BM, von Minckwitz G, Schwabe M, Roller M, Darb-Esfahani S, Ataseven B, du Bois A, Fissler-Eckhoff A, Gerber B et al. 2011 Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. Breast Cancer Research and Treatment 130 477-487. (doi:10.1007/s10549-011-1715-8)
101. Luo X, Shi YX, Li ZM & Jiang WQ 2010 Expression and clinical significance of androgen receptor in triple negative breast cancer. Chinese Journal of Cancer 29 585-590. (doi:10.5732/cjc.009.10673)
102. Lyu S, Yu Q, Ying G, Wang S, Wang Y, Zhang J & Niu Y 2014 Androgen receptor decreases CMYC and KRAS expression by upregulating let-7a expression in ERK-, PRK-, ARC+ breast cancer. International Journal of Oncology 44 229-237. (doi:10.3892/ijo.2013.2151)
103. Macedo LF, Guo Z, Tilghman SL, Sabnis GJ, Qiu Y & Brodie A 2006 Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. Cancer Research 66 7775-7782. (doi:10.1158/0008-5472.CAN-05-3984)
104. Mackenzie PI, Hu DG & Gardner-Stephen DA 2010 The regulation of UDP-glucuronosyltransferase genes by tissue-specific and ligand-activated transcription factors. Drug Metabolism Reviews 42 99-109. (doi:10.3109/ 03602530903209544)
105. Maggiolini M, Donze O, Jeannin E, Ando S & Picard D 1999 Adrenal androgens stimulate the proliferation of breast cancer cells as direct activators of estrogen receptor α. Cancer Research 59 4864-4869. (Pubitemid 29472889)
106. Manjer J, Johansson R, Berglund G, Janzon L, Kaaks R, Agren A & Lenner P 2003 Postmenopausal breast cancer risk in relation to sex steroid hormones, prolactin and SHBG (Sweden). Cancer Causes & Control 14 599-607. (doi:10.1023/A:1025671317220)
107. McNamara KM, Harwood DT, Simanainen U, Walters KA, Jimenez M & Handelsman DJ 2010 Measurement of sex steroids in murine blood and reproductive tissues by liquid chromatography tandem mass spectrometry. Journal of Steroid Biochemistry and Molecular Biology 121 611-618. (doi:10.1016/j.jsbmb.2010.02. 001)
108. McNamara K, Yoda T, Miki Y, Chanplakorn N, Wongwaisayawan S, Incharoen P, Kongdan Y, Wang L, Takagi K, Mayu T et al. 2013a Androgenic pathway in triple negative invasive ductal tumours: its correlation with tumour cell proliferation. Cancer Science 104 639-646. (doi:10.1111/cas.12121)
109. McNamara KM, Nakamura Y, Miki Y & Sasano H 2013b Phase two steroid metabolism and its roles in breast and prostate cancer patients. Frontiers in Endocrinology 4 116. (doi:10.3389/fendo.2013.00116)
110. McNamara KM, Yoda T, Nurani AM, Shibahara Y, Miki Y, Wang L, Nakamura Y, Suzuki K, Yang Y, Abe E et al. 2014 Androgenic pathways in the progression of triple-negative breast carcinoma: a comparison between aggressive and non-aggressive subtypes. Breast Cancer Research and Treatment 145 281-293. (doi:10.1007/s10549-014-2942-6)
111. Mester J & Eng C 2013 When overgrowth bumps into cancer: the PTEN-opathies. American Journal of Medical Genetics. Part C, Seminars in Medical Genetics 163C 114-121. (doi:10.1002/ajmg.c.31364)
112. Micello D, Marando A, Sahnane N, Riva C, Capella C & Sessa F 2010 Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers. Virchows Archiv 457 467-476. (doi:10.1007/s00428-010-0964-y)
113. Micheli A, Muti P, Secreto G, Krogh V, Meneghini E, Venturelli E, Sieri S, Pala V & Berrino F 2004 Endogenous sex hormones and subsequent breast cancer in premenopausal women. International Journal of Cancer 112 312-318. (doi:10.1002/ijc.20403)
114. Missmer SA, Eliassen AH, Barbieri RL & Hankinson SE 2004 Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. Journal of the National Cancer Institute 96 1856-1865. (doi:10.1093/jnci/djh336)
115. Moinfar F, Okcu M, Tsybrovskyy O, Regitnig P, Lax SF, Weybora W, Ratschek M, Tavassoli FA & Denk H 2003 Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. Cancer 98 703-711. (doi:10.1002/cncr.11532)
116. Moore NL, Buchanan G, Harris JM, Selth LA, Bianco-Miotto T, Hanson AR, Birrell SN, Butler LM, Hickey TE & Tilley WD 2012 An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity. Endocrine-Related Cancer 19 599-613. (doi:10.1530/ERC-12-0065)
117. Mrklic I, Pogorelic Z, Capkun V & Tomic S 2012 Expression of androgen receptors in triple negative breast carcinomas. Acta Histochemica 115 344-348. (doi:10.1016/j.acthis.2012.09.006)
118. Mueller A & Gooren L 2008 Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones. European Journal of Endocrinology 159 197-202. (doi:10.1530/EJE-08-0289)
119. Naderi A & Hughes-Davies L 2008 A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. Neoplasia 10 542-548. (Pubitemid 351770298)
120. Naderi A, Chia KM & Liu J 2011 Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer. Breast Cancer Research 13 R36. (doi:10.1186/bcr2858)
121. Naderi A, Meyer M & Dowhan DH 2012 Cross-regulation between FOXA1 and ErbB2 signaling in estrogen receptor-negative breast cancer. Neoplasia 14 283-296.
122. Nagasaki S, Miki Y, Akahira J, Suzuki T & Sasano H 2009 17β-hydroxysteroid dehydrogenases in human breast cancer. Annals of the New York Academy of Sciences 1155 25-32. (doi:10.1111/j.1749-6632.2008.03682.x)
123. Need EF, Selth LA, Harris TJ, Birrell SN, Tilley WD & Buchanan G 2012 Research resource: interplay between the genomic and transcriptional networks of androgen receptor and estrogen receptor α in luminal breast cancer
124. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F et al. 2006 A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10 515-527. (doi:10.1016/j.ccr.2006.10.008)
125. Ni M, Chen Y, Lim E, Wimberly H, Bailey ST, Imai Y, Rimm DL, Liu XS & Brown M 2011 Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell 20 119-131. (doi:10.1016/j.ccr.2011.05.026)
126. Ni M, Chen Y, Fei T, Li D, Lim E, Liu XS & Brown M 2013 Amplitude modulation of androgen signaling by c-MYC. Genes and Development 27 734-748. (doi:10.1101/gad.209569.112)
127. Niemeier LA, Dabbs DJ, Beriwal S, Striebel JM& Bhargava R 2010 Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Modern Pathology 23 205-212. (doi:10.1038/modpathol.2009.159)
128. Ochnik AM, Moore NL, Jankovic-Karasoulos T, Bianco-Miotto T, Ryan NK, Thomas MR, Birrell SN, Butler LM, Tilley WD & Hickey TE 2014 Antiandrogenic actions of medroxyprogesterone acetate on epithelial cells within normal human breast tissues cultured ex vivo. Menopause 21 79-88. (doi:10.1097/GME. 0b013e3182936ef4)
129. Ogawa Y, Hai E, Matsumoto K, Ikeda K, Tokunaga S, Nagahara H, Sakurai K, Inoue T & Nishiguchi Y 2008 Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. International Journal of Clinical Oncology 13 431-435. (doi:10.1007/s10147-008-0770-6)
130. Ortmann J, Prifti S, Bohlmann MK, Rehberger-Schneider S, Strowitzki T & Rabe T 2002 Testosterone and 5 α-dihydrotestosterone inhibit in vitro growth of human breast cancer cell lines. Gynecological Endocrinology 16 113-120. (doi:10.1080/713603030)
131. O'Shaughnessy J, Campone M, Brain E, Neven P, Hayes DF, Bondarenko I, Griffin TW, Martin JL, De Porre P, Kheoh T et al. 2014 Randomized phase 2 study of abiraterone acetate with or without exemestane in postmenopausal patients with estrogen receptor-positive metastatic breast cancer. American Society of Clinical Oncology 2014 Annual Meeting. Journal of Clinical Oncology 32 (suppl) abstr 519.
132. Overmoyer B, Sanz-Altamira P, Taylor R, Hancock ML, Dalton JT, Johnston MA & Steiner MS 2014 Enobosarm - a targeted therapy for metastatic androgen receptor positive breast cancer. American Society of Clinical Oncology 2014 Annual Meeting. Journal of Clinical Oncology 32 (suppl) abstr 568.
133. Panet-Raymond V, Gottlieb B, Beitel LK, Pinsky L & Trifiro MA 2000 Interactions between androgen and estrogen receptors and the effects on their transactivational properties. Molecular and Cellular Endocrinology 167 139-150. (doi:10.1016/S0303-7207(00)00279-3)
134. Park JJ, Irvine RA, Buchanan G, Koh SS, Park JM, Tilley WD, Stallcup MR, Press MF & Coetzee GA 2000 Breast cancer susceptibility gene 1 (BRCAI) is a coactivator of the androgen receptor. Cancer Research 60 5946-5949.
135. Park S, Koo J, Park HS, Kim JH, Choi SY, Lee JH, Park BW & Lee KS 2010 Expression of androgen receptors in primary breast cancer. Annals of Oncology 21 488-492. (doi:10.1093/annonc/mdp510)
136. Park S, Koo JS, Kim MS, Park HS, Lee JS, Lee JS, Kim SI, Park BW & Lee KS 2011 Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. Annals of Oncology 22 1755-1762. (doi:10.1093/annonc/mdq678)
137. Park S, Park HS, Koo JS, Yang WI, Kim SI & Park BW 2012 Higher expression of androgen receptor is a significant predictor for better endocrine-responsiveness in estrogen receptor-positive breast cancers. Breast Cancer Research and Treatment 133 311-320. (doi:10.1007/s10549-011-1950-z)
138. Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z et al. 2009 Supervised risk predictor of breast cancer based on intrinsic subtypes. Journal of Clinical Oncology 27 1160-1167. (doi:10.1200/JCO.2008.18.1370)
139. Penning TM, Burczynski ME, Jez JM, Hung CF, Lin HK, Ma H, Moore M, Palackal N & Ratnam K 2000 Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochemical Journal 351 67-77. (doi:10.1042/0264-6021:3510067)
140. Perou CM 2011 Molecular stratification of triple-negative breast cancers. Oncologist 16 (Suppl 1) 61-70. (doi:10.1634/theoncologist.2011-S1-61)
141. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA et al. 2000 Molecular portraits of human breast tumours. Nature 406 747-752. (doi:10.1038/35021093)
142. Peters AA, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera MM, Harris JM, Jindal S, Segara D, Jia L, Moore NL et al. 2009 Androgen receptor inhibits estrogen receptor-α activity and is prognostic in breast cancer. Cancer Research 69 6131-6140. (doi:10.1158/0008-5472.CAN-09-0452)
143. Peters KM, Edwards SL, Nair SS, French JD, Bailey PJ, Salkield K, Stein S, Wagner S, Francis GD, Clark SJ et al. 2012 Androgen receptor expression predicts breast cancer survival: the role of genetic and epigenetic events. BMC Cancer 12 132. (doi:10.1186/1471-2407-12-132)
144. Poulin R, Baker D & Labrie F 1988 Androgens inhibit basal and estrogeninduced cell proliferation in the ZR-75-1 human breast cancer cell line. Breast Cancer Research and Treatment 12 213-225. (doi:10.1007/BF01805942)
145. Prat A & Perou CM 2011 Deconstructing the molecular portraits of breast cancer. Molecular Oncology 5 5-23. (doi:10.1016/j.molonc.2010.11.003)
146. Pristauz G, Petru E, Stacher E, Geigl JB, Schwarzbraun T, Tsybrovskyy O, Winter R & Moinfar F 2010 Androgen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 mutations. Histopathology 57 877-884. (doi:10.1111/j.1365-2559.2010.03724.x)
147. Qi JP, Yang YL, Zhu H, Wang J, Jia Y, Liu N, Song YJ, Zan LK, Zhang X, Zhou M et al. 2012 Expression of the androgen receptor and its correlation with molecular subtypes in 980 Chinese breast cancer patients. Breast Cancer 6 1-8. (doi:10.4137/BCBCR.S8323)
148. Qu Q, Mao Y, Fei XC & Shen KW 2013 The impact of androgen receptor expression on breast cancer survival: a retrospective study and meta-analysis. PLoS ONE 8 e82650. (doi:10.1371/journal.pone.0082650)
149. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF & Ellis IO 2007 Prognostic markers in triple-negative breast cancer. Cancer 109 25-32. (doi:10.1002/cncr.22381)
150. Robinson JL & Carroll JS 2012 FoxA1 is a key mediator of hormonal response in breast and prostate cancer. Frontiers in Endocrinology 3 68. (doi:10.3389/fendo.2012.00068)
151. Robinson JL, MacArthur S, Ross-Innes CS, Tilley WD, Neal DE, Mills IG & Carroll JS 2011 Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO Journal 30 3019-3027. (doi:10.1038/emboj.2011.216)
152. de Ronde W, van der Schouw YT, Pols HA, Gooren LJ, Muller M, Grobbee DE & de Jong FH 2006 Calculation of bioavailable and free testosterone in men: a comparison of 5 published algorithms. Clinical Chemistry 52 1777-1784. (doi:10.1373/clinchem.2005.063354)
153. Rothman MS, Carlson NE, Xu M, Wang C, Swerdloff R, Lee P, Goh VH, Ridgway EC & Wierman ME 2011 Reexamination of testosterone, dihydrotestosterone, estradiol and estrone levels across the menstrual cycle and in postmenopausal women measured by liquid chromatography-tandem mass spectrometry. Steroids 76 177-182. (doi:10.1016/j.steroids.2010.10.010)
154. Sanga S, Broom BM, Cristini V & Edgerton ME 2009 Gene expression metaanalysis supports existence of molecular apocrine breast cancer with a role for androgen receptor and implies interactions with ErbB family. BMC Medical Genomics 2 59. (doi:10.1186/1755-8794-2-59)
155. Santagata S, Thakkar A, Ergonul A, Wang B, Woo T, Hu R, Harrell JC, McNamara G, Schwede M, Culhane AC et al. 2014 Taxonomy of breast cancer based on normal cell phenotype predicts outcome. Journal of Clinical Investigation 124 859-870. (doi:10.1172/JCI70941)
156. Santen RJ, Brodie H, Simpson ER, Siiteri PK & Brodie A 2009 History of aromatase: saga of an important biological mediator and therapeutic target. Endocrine Reviews 30 343-375. (doi:10.1210/er.2008-0016)
157. Sartorius G, Ly LP, Sikaris K, McLachlan R & Handelsman DJ 2009 Predictive accuracy and sources of variability in calculated free testosterone estimates. Annals of Clinical Biochemistry 46 137-143. (doi:10.1258/acb.2008. 008171)
158. Sasano H, Miki Y, Nagasaki S & Suzuki T 2009 In situ estrogen production and its regulation in human breast carcinoma: from endocrinology to intracrinology. Pathology International 59 777-789. (doi:10.1111/j.1440-1827. 2009.02444.x)
159. Schippinger W, Regitnig P, Dandachi N, Wernecke KD, Bauernhofer T, Samonigg H & Moinfar F 2006 Evaluation of the prognostic significance of androgen receptor expression in metastatic breast cancer. Virchows Archiv 449 24-30. (doi:10.1007/s00428-006-0213-6)
160. Scorilas A, Bharaj B, Giai M & Diamandis EP 2001 Codon 89 polymorphism in the human 5 α-reductase gene in primary breast cancer. British Journal of Cancer 84 760-767. (doi:10.1054/bjoc.2000.1681)
161. Shibahara Y, Miki Y, Onodera Y, Hata S, Chan MS, Yiu CC, Loo TY, Nakamura Y, Akahira J, Ishida T et al. 2012 Aromatase inhibitor treatment of breast cancer cells increases the expression of let-7f, a microRNA targeting CYP19A1. Journal of Pathology 227 357-366. (doi:10.1002/path.4019)
162. Shibahara Y, Miki Y, Sakurada C, Uchida K, Hata S, McNamara K, Yoda T, Takagi K, Nakamura Y, Suzuki T et al. 2013 Androgen and androgenmetabolizing enzymes in metastasized lymph nodes of breast cancer. Human Pathology 44 2338-2345. (doi:10.1016/j.humpath.2013.04.021)
163. Shibuya R, Suzuki T,Miki Y, Yoshida K, Moriya T, Ono K, Akahira J, Ishida T, Hirakawa H, Evans DB et al. 2008 Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast. Endocrine-Related Cancer 15 113-124. (doi:10.1677/ERC-07-0092)
164. Shufelt CL & Braunstein GD 2008 Testosterone and the breast. Menopause International 14 117-122. (doi:10.1258/mi.2008.008015)
165. Sieri S, Krogh V, Bolelli G, Abagnato CA, Grioni S, Pala V, Evangelista A, Allemani C, Micheli A, Tagliabue G et al. 2009 Sex hormone levels, breast cancer risk, and cancer receptor status in postmenopausal women: the ORDET cohort. Cancer Epidemiology, Biomarkers & Prevention 18 169-176. (doi:10.1158/1055-9965.EPI-08-0808)
166. Soiland H, Korner H, Skaland I, Janssen EA, Gudlaugsson E, Varhaug JE, Baak JP & Soreide JA 2008 Prognostic relevance of androgen receptor detection in operable breast cancer. Journal of Surgical Oncology 98 551-558. (doi:10.1002/jso.21156)
167. Soreide JA, Lea OA, Varhaug JE, Skarstein A & Kvinnsland S 1992 Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment. European Journal of Surgical Oncology 18 112-118.
168. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS et al. 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS 98 10869-10874. (doi:10.1073/pnas.191367098)
169. Sparks R, Ulrich CM, Bigler J, Tworoger SS, Yasui Y, Rajan KB, Porter P, Stanczyk FZ, Ballard-Barbash R, Yuan X et al. 2004 UDP-glucuronosyl-transferase and sulfotransferase polymorphisms, sex hormone concentrations, and tumor receptor status in breast cancer patients. Breast Cancer Research 6 R488-R498. (doi:10.1186/bcr818)
170. Spurdle AB, Hopper JL, Chen X, Dite GS, McCredie MR, Giles GG, Venter DJ, Southey MC, Purdie DM & Chenevix-Trench G 2001 The steroid 5α-reductase type II TA repeat polymorphism is not associated with risk of breast or ovarian cancer in Australian women. Cancer Epidemiology, Biomarkers & Prevention 10 1287-1293. (Pubitemid 34027761)
171. Sturgeon SR, Potischman N, Malone KE, Dorgan JF, Daling J, Schairer C & Brinton LA 2004 Serum levels of sex hormones and breast cancer risk in premenopausal women: a case-control study (USA). Cancer Causes & Control 15 45-53. (doi:10.1023/B:CACO.0000016574.79728.11)
172. Suzuki T, Darnel AD, Akahira JI, Ariga N, Ogawa S, Kaneko C, Takeyama J, Moriya T & Sasano H 2001 5α-reductases in human breast carcinoma: possible modulator of in situ androgenic actions. Journal of Clinical Endocrinology and Metabolism 86 2250-2257. (doi:10.1210/jcem.86.5.7444)
173. Suzuki T, Miki Y, Nakata T, Shiotsu Y, Akinaga S, Inoue K, Ishida T, Kimura M, Moriya T & Sasano H 2003 Steroid sulfatase and estrogen sulfotransferase in normal human tissue and breast carcinoma. Journal of Steroid Biochemistry and Molecular Biology 86 449-454. (doi:10.1016/S0960-0760(03) 00356-X)
174. Suzuki T, Miki Y, Nakamura Y, Moriya T, Ito K, Ohuchi N & Sasano H 2005 Sex steroid-producing enzymes in human breast cancer. Endocrine-Related Cancer 12 701-720. (doi:10.1677/erc.1.00834)
175. Suzuki T, Miki Y, Moriya T, Akahira J, Ishida T, Hirakawa H, Yamaguchi Y, Hayashi S & Sasano H 2006 5α-reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production. International Journal of Cancer 120 285-291. (doi:10.1002/ijc.22317)
176. Suzuki T, Miki Y, Takagi K, Hirakawa H, Moriya T, Ohuchi N & Sasano H 2010 Androgens in human breast carcinoma. Medical Molecular Morphology 43 75-81. (doi:10.1007/s00795-010-0494-3)
177. Szelei J, Jimenez J, Soto AM, Luizzi MF & Sonnenschein C 1997 Androgen-induced inhibition of proliferation in human breast cancer MCF7 cells transfected with androgen receptor. Endocrinology 138 1406-1412. (doi:10.1210/endo.138.4.5047)
178. Tang D, Xu S, Zhang Q & Zhao W 2012 The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer. Medical Oncology 29 526-533. (doi:10.1007/s12032-011-9948-2)
179. Tarulli GA, van Butler LM, Tilley WD & Hickey TE 2014 Bringing androgens up a notch in breast cancer. Endocrine-Related Cancer 21 T183-T196. (doi:10.1530/ERC-14-0248)
180. Teulings FA, van Gilse HA, Henkelman MS, Portengen H & Alexieva-Figusch J 1980 Estrogen, androgen, glucocorticoid, and progesterone receptors in progestin-induced regression of human breast cancer. Cancer Research 40 2557-2561. (Pubitemid 10082284)
181. Thomas HV, Key TJ, Allen DS, Moore JW, Dowsett M, Fentiman IS & Wang DY 1997 A prospective study of endogenous serum hormone concentrations and breast cancer risk in premenopausal women on the island of Guernsey. British Journal of Cancer 75 1075-1079. (doi:10.1038/bjc.1997.183)
182. Tormey DC, Lippman ME, Edwards BK & Cassidy JG 1983 Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer. Annals of Internal Medicine 98 139-144. (doi:10.7326/0003-4819-98-2-139)
183. Tsutsumi Y 2012 Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma. Japanese Journal of Clinical Oncology 42 375-386. (doi:10.1093/jjco/hys034)
184. Utsumi T, Yoshimura N, Takeuchi S, Ando J, Maruta M, Maeda K & Harada N 1999 Steroid sulfatase expression is an independent predictor of recurrence in human breast cancer. Cancer Research 59 377-381. (Pubitemid 29048871)
185. Vera-Badillo FE, Templeton AJ, de Gouveia P, Diaz-Padilla I, Bedard PL, Al-Mubarak M, Seruga B, Tannock IF, Ocana A & Amir E 2014 Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. Journal of the National Cancer Institute 106 djt319. (doi:10.1093/jnci/djt319)
186. Vihko P, Herrala A, Harkonen P, Isomaa V, Kaija H, Kurkela R, Li Y, Patrikainen L, Pulkka A, Soronen P et al. 2005 Enzymes as modulators in malignant transformation. Journal of Steroid Biochemistry and Molecular Biology 93 277-283. (doi:10.1016/j.jsbmb.2005.01.002)
187. Wang B, Mi M, Wang J, Wei N, Zhang Q, Zhu J, Yang S, Guo B, Xu J & Yang X 2009 Does the increase of endogenous steroid hormone levels also affect breast cancer risk in Chinese women? A case-control study in Chongqing, China. International Journal of Cancer 124 1892-1899. (doi:10.1002/ijc.24132)
188. Wang Y, Romigh T, He X, Tan MH, Orloff MS, Silverman RH, Heston WD & Eng C 2011 Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers. Oncogene 30 4327-4338. (doi:10.1038/onc.2011.144)
189. Wang Y, He X, Yu Q & Eng C 2013a Androgen receptor-induced tumor suppressor, KLLN, inhibits breast cancer growth and transcriptionally activates p53/p73-mediated apoptosis in breast carcinomas. Human Molecular Genetics 22 2263-2272. (doi:10.1093/hmg/ddt077)
190. Wang Y, Yu Q, He XJ, Romigh T, Altemus J & Eng C 2013b Activation of AR sensitizes breast carcinomas to NVP-BEZ235's therapeutic effect mediated by PTEN and KLLN upregulation. Molecular Cancer Therapeutics 13 517-527. (doi:10.1158/1535-7163.MCT-13-0655)
191. Witzel I, Graeser M, Karn T, Schmidt M, Wirtz R, Schutze D, Rausch A, Janicke F, Milde-Langosch K & Muller V 2013 Androgen receptor expression is a predictive marker in chemotherapy-treated patients with endocrine receptor-positive primary breast cancers. Journal of Cancer Research and Clinical Oncology 139 809-816. (doi:10.1007/s00432-013-1382-8)
192. Yang C, Hamajima N, Iwata H, Saito T, Matsuo K, Hirose K, Inoue M, Takezaki T & Tajima K 2002 A49T, V89L and TA repeat polymorphisms of steroid 5α-reductase type II and breast cancer risk in Japanese women. Breast Cancer Research 4 R8. (doi:10.1186/bcr445)
193. Yu H, Shu XO, Shi R, Dai Q, Jin F, Gao YT, Li BD & Zheng W 2003 Plasma sex steroid hormones and breast cancer risk in Chinese women. International Journal of Cancer 105 92-97. (doi:10.1002/ijc.11034)
194. Yu Q, Niu Y, Liu N, Zhang JZ, Liu TJ, Zhang RJ, Wang SL, Ding XM & Xiao XQ 2011 Expression of androgen receptor in breast cancer and its significance as a prognostic factor. Annals of Oncology 22 1288-1294. (doi:10.1093/annonc/mdq586)
195. Zeleniuch-Jacquotte A, Shore RE, Koenig KL, Akhmedkhanov A, Afanasyeva Y, Kato I, Kim MY, Rinaldi S, Kaaks R & Toniolo P 2004 Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study. British Journal of Cancer 90 153-159. (doi:10.1038/sj.bjc. 6601517)
196. Zeleniuch-Jacquotte A, Gu Y, Shore RE, Koenig KL, Arslan AA, Kato I, Rinaldi S, Kaaks R & Toniolo P 2005 Postmenopausal levels of sex hormones and risk of breast carcinoma in situ: results of a prospective study. International Journal of Cancer 114 323-327. (doi:10.1002/ijc.20694)
197. Zeleniuch-Jacquotte A, Afanasyeva Y, Kaaks R, Rinaldi S, Scarmo S, Liu M, Arslan AA, Toniolo P, Shore RE & Koenig KL 2012 Premenopausal serum androgens and breast cancer risk: a nested case-control study. Breast Cancer Research 14 R32. (doi:10.1186/bcr3117)
198. Zhao GL, Luu-The L, Van Fan Z, Fernand L & Georges P 2010 Expression of 5α-reductase type 1 in breast cancer and adjacent non-malignant tissue: an immunohistochemical study. Hormone Molecular Biology and Clinical Investigation 3 411-415. (doi:10.1515/HMBCI.2010.046)